SCHEMBL18019146

SCHEMBL18019146

[N-]=[N+]=NCCCCCC(=O)NN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.44
KDM4E B2RXH2 2/20 0.39
CTSD P07339 1/20 0.39
KDM5C P41229 1/20 0.39
PHF8 Q9UPP1 1/20 0.39
KDM2A Q9Y2K7 1/20 0.39
CNR2 P34972 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
IDUA P35475 2/20 0.35
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HSP90AA1 P07900 1/20 0.31
HPSE Q9Y251 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14129575 1.00 ALDH1A1 (0.47) ALDH1A1GAAKDM4ECTSDKDM5C
SCHEMBL26667252 0.98 ALDH1A1 (0.44) ALDH1A1GAAKDM4ECTSDKDM5C
SCHEMBL20773993 0.92 KDM4E (0.41) ALDH1A1GAAKDM4ECTSDKDM5C
SCHEMBL14328132 0.82 HDAC8 (0.60) KDM4EHDAC3HDAC1HDAC2HDAC8
SCHEMBL19079656 0.81 CNR2 (0.42) CNR2HDAC3HDAC1HDAC2HDAC8
SCHEMBL25257297 0.79 IDUA (0.38) ALDH1A1KDM4ECNR2IDUALMNA
SCHEMBL19194629 0.79 IDUA (0.38) ALDH1A1KDM4ECNR2IDUALMNA
SCHEMBL30684791 0.79 IDUA (0.38) ALDH1A1KDM4ECNR2IDUALMNA
SCHEMBL13772507 0.79 IDUA (0.38) ALDH1A1KDM4ECNR2IDUALMNA
SCHEMBL18635573 0.79 IDUA (0.38) ALDH1A1KDM4ECNR2IDUALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110591078-B Preparation method of reduction/pH dual-responsiveness adriamycin prodrug 苏州大学 2021-11-05 CN claimed
CN-107233309-B Mixed micelle medicine based on doxorubicin prodrug and gene co-loading and preparation method thereof 苏州大学 2021-03-02 CN claimed
CN-110591078-A Preparation method of reduction/pH dual-responsiveness adriamycin prodrug 苏州大学 2019-12-20 CN claimed
US-11786525-B1 High-efficiency anti-tumor nano-drug delivery system containing hydralazine and preparation method thereof SHANGHAI INSTITUTE FOR ADVANCED STUDY ZHE JIANG UNIVERSITY (CN) 2023-10-17 US disclosed
CN-115120573-B High-efficiency anti-tumor nano drug-loading system containing hydralazine and preparation method thereof 上海浙江大学高等研究院 2022-12-20 CN disclosed
CN-115120573-A High-efficiency anti-tumor nano drug-loading system containing hydralazine and preparation method thereof 上海浙江大学高等研究院 2022-09-30 CN disclosed
CN-110591078-B Preparation method of reduction/pH dual-responsiveness adriamycin prodrug 苏州大学 2021-11-05 CN disclosed
CN-107233309-B Mixed micelle medicine based on doxorubicin prodrug and gene co-loading and preparation method thereof 苏州大学 2021-03-02 CN disclosed
US-10632206-B2 Zwitterionic polymers with therapeutic moieties UNIVERSITY OF MASSACHUSETTS (US) 2020-04-28 US disclosed
US-10632206-B2 Zwitterionic polymers with therapeutic moieties UNIVERSITY OF MASSACHUSETTS (US) 2020-04-28 US disclosed
CN-110591078-A Preparation method of reduction/pH dual-responsiveness adriamycin prodrug 苏州大学 2019-12-20 CN disclosed
EP-2358770-B1 ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES UNIV MASSACHUSETTS (US) 2017-03-15 EP disclosed
US-20160346400-A1 ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES UNIVERSITY OF MASSACHUSETTS 2016-12-01 US disclosed
US-20160346400-A1 ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES UNIVERSITY OF MASSACHUSETTS 2016-12-01 US disclosed
US-9416210-B2 Zwitterionic polymers with therapeutic moieties THE UNIVERSITY OF MASSACHUSETTS (US) 2016-08-16 US disclosed
US-9416210-B2 Zwitterionic polymers with therapeutic moieties THE UNIVERSITY OF MASSACHUSETTS (US) 2016-08-16 US disclosed
US-20110319569-A1 ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES UNIVERSITY OF MASSACHUSETTS (US) 2011-12-29 US disclosed
US-20110319569-A1 ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES UNIVERSITY OF MASSACHUSETTS (US) 2011-12-29 US disclosed
EP-2358770-A2 ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES University of Massachusetts (US) 2011-08-24 EP disclosed
WO-2010068862-A2 ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES UNIVERSITY OF MASSACHUSETTS (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10632206-B2 Zwitterionic polymers with therapeutic moieties PHOSPHO1, PCTP, PAICS ALDH1A1 2784/4885GAA 3096/4885KDM4E 1529/4885
US-20160346400-A1 ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES PHOSPHO1, PCTP, PAICS ALDH1A1 2784/4885GAA 3096/4885KDM4E 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.